Kathleen M. McAndrews

Nov 6, 2024 | digitalcommons.library.tmc.edu | Krishnan K Mahadevan |Kathleen M. McAndrews |Valerie S LeBleu |Sujuan Yang

AbstractThe KRASG12D mutation is present in nearly half of pancreatic adenocarcinomas (PDAC). We investigated the effects of inhibiting the KRASG12D mutant protein with MRTX1133, a non-covalent small molecule inhibitor of KRASG12D, on early and advanced PDAC and its influence on the tumor microenvironment.

Aug 24, 2023 | cell.com | Krishnan K Mahadevan |Kathleen M. McAndrews |Valerie S LeBleu |Sujuan Yang

The KRASG12D mutation is present in nearly half of pancreatic adenocarcinomas (PDAC). We investigated the effects of inhibiting the KRASG12D mutant protein with MRTX1133, a non-covalent small molecule inhibitor of KRASG12D, on early and advanced PDAC and its influence on the tumor microenvironment.

Feb 16, 2023 | biorxiv.org | Kathleen M. McAndrews |Valerie S LeBleu |Sujuan Yang |Krishnan K Mahadevan

New Results doi: https://doi.org/10.1101/2023.02.15.528757 AbstractPancreatic ductal adenocarcinoma (PDAC) is associated with mutations in Kras, a known oncogenic driver of PDAC; and the KRASG12D mutation is present in nearly half of PDAC patients. Recently, a non-covalent small molecule inhibitor (MRTX1133) was identified with specificity to the KrasG12D mutant protein.

Feb 16, 2023 | biorxiv.org | Krishnan K Mahadevan |Kathleen M. McAndrews |Valerie S LeBleu |Sujuan Yang

New Results doi: https://doi.org/10.1101/2023.02.15.528757 AbstractPancreatic ductal adenocarcinoma (PDAC) is associated with mutations in Kras, a known oncogenic driver of PDAC; and the KRASG12D mutation is present in nearly half of PDAC patients. Recently, a non-covalent small molecule inhibitor (MRTX1133) was identified with specificity to the KrasG12D mutant protein.